Histone deacetylase inhibitors (HDACis) are being recognized as a potentially effective treatment approach for peripheral T-cell lymphomas (PTCLs), a heterogeneous group of aggressive malignancies with an unfavorable prognosis. Recent evidence has shown that HDACis are effective in treating PTCL, especially in cases where the disease has relapsed or is resistant to conventional treatments. Several clinical trials have demonstrated that HDACis, such as romidepsin and belinostat, can elicit long-lasting positive outcomes in individuals with PTCLs, either when used alone or in conjunction with conventional chemotherapy. They exert their anti-tumor effects by regulating gene expression through the inhibition of histone deacetylases, which leads to cell cycle arrest, induction of programmed cell death, and,the transformation of cancerous T cells, as demonstrated by gene expression profile studies. Importantly, besides clinical trials, real-world evidence indicated that the utilization of HDACis presents a significant and beneficial treatment choice for PTCLs. However, although HDACis showed potential effectiveness, they could not cure most patients. Therefore, new combinations with conventional drugs as well as new targeted agents are under investigation.
组蛋白去乙酰化酶抑制剂（HDACis）正被视为治疗外周T细胞淋巴瘤（PTCLs）的一种潜在有效方法。PTCLs是一组异质性强、预后不良的侵袭性恶性肿瘤。近期证据表明，HDACis对PTCL具有治疗效果，尤其适用于疾病复发或对常规治疗产生耐药性的病例。多项临床试验证实，罗米地辛和贝利司他等HDACis单药或联合常规化疗，均能在PTCL患者中引发持久的积极疗效。基因表达谱研究显示，其通过抑制组蛋白去乙酰化酶调控基因表达，从而发挥抗肿瘤作用，具体机制包括诱导细胞周期停滞、程序性细胞死亡以及恶性T细胞的转化。值得注意的是，除临床试验外，真实世界证据也表明HDACis为PTCL提供了重要且有益的治疗选择。然而，尽管HDACis显示出潜在疗效，但尚不能治愈多数患者。因此，目前正在研究其与传统药物及新型靶向药物的联合治疗方案。
Histone Deacetylase Inhibitors for Peripheral T-Cell Lymphomas
肿瘤(癌症)患者之家